Pharmacogenomic Inequalities: Strategies for Justice in Biomedical Research and Healthcare

Main Article Content

Giovanni De Grandis

Abstract

The paper discusses the possibility that the benefits of pharmacogenomics will not be distributed equally and will create orphan populations. I argue that since these inequalities are not substantially different from those produced by ‘traditional’ drugs and are not generated with the intention to discriminate, their production needs not be unethical. Still, the final result is going against deep-seated moral feelings and intuitions, as well as broadly accepted principles of just distribution of health outcomes and healthcare. I thus propose two provisos that would prevent the most offensive outcomes and moderate the scope of the produced inequalities. The first proviso rejects pharmacogenomics innovations that worsen existing group inequalities and aggravate the disadvantage of communities with a history of discrimination. The second proviso requires that there is a strategy in place to even out as much as possible the distribution of benefits in the future and that a system of compensations (in terms of healthcare services) is in place for pharmacogenomic orphans. Given that only one moral problem generated by pharmacogenomics has been tackled, the list of provisos might be expanded when other issues are considered.

Downloads

Download data is not yet available.

Article Details

How to Cite
De Grandis, Giovanni. 2017. “Pharmacogenomic Inequalities: Strategies for Justice in Biomedical Research and Healthcare”. Diametros, no. 51 (March):153-72. https://doi.org/10.13153/diam.51.2017.1036.
Section
Equality and Decency in Healthcare
Author Biography

Giovanni De Grandis, Norwegian University of Science and Technology

Dr. Giovanni De Grandis Postdoctoral researcherReset research group on the ethos of technology Department of Philosophy and Religious StudiesNorwegian University of Science and TechnologyE-mail: giovanni.de.grandis@ntnu.no
Share |

References

Anand, Peter, Sen [2004] – S. Anand, F. Peter and A.K. Sen, Public health, ethics, and equity, Oxford University Press, Oxford 2004.
View in Google Scholar

Annas, Elias [2015] – G. Annas and S. Elias, Genomics Messages. How the Evolving Science of Genetics affects our Health, Families, and Future, HarperOne, New York 2015.
View in Google Scholar

Bartley [2003] – M. Bartley, Health inequality: an introduction to theories, concepts and methods, Polity Press, Cambridge, UK, Malden, MA 2003.
View in Google Scholar

Bayer, Galea [2015] – R. Bayer and S. Galea, “Public health in the precision-medicine era,” New England Journal of Medicine (373/6) 2015, p. 499–501.
View in Google Scholar

BIS [2010] – Department for Business Innovation and Skills, “Life Sciences in the UK – Economic analysis and evidence for ‘Life Sciences 2010: Delivering the Blueprint’,” Economic Paper NO. 2, 2010.
View in Google Scholar

Black et al. [1980] – D. Black, J. Morris, C. Smith and P. Townsend, Inequalities in health: report of a Research Working Group, Department of Health and Social Security, London 1980.
View in Google Scholar

Braun et al. [2010] – M.M. Braun, S. Farag-El-Massah, K. Xu and T.R. Coté, “Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years,” Nature Reviews Drug Discovery (9/7) 2010, p. 519–522.
View in Google Scholar

Braveman [2006] – P. Braveman, “Health disparities and health equity: concepts and measurement,“ Annual Review of Public Health (27) 2006, p. 167–194.
View in Google Scholar

Brody [2007] – H. Brody, Hooked. Ethics, the Medical Profession, and the Pharmaceutical Industry, Rowman & Littlefield, Lanham MD 2007.
View in Google Scholar

Buchanan et al. [2002] – A.E. Buchanan, A. Califano, J.P. Kahn, B.A. Brody, J.A. Robertson, and E. McPherson, “Pharmacogenetics: ethical issues and policy options,” Kennedy Institute of Ethics Journal (12/1) 2002, p. 1–15.
View in Google Scholar

CML [2013] – Experts in Chronic Myeloid Leukemia, “The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts,” Blood (121/22) 2013, p. 4439–4442.
View in Google Scholar

Cohn, Henderson, Appelbaum [2017] – E.G. Cohn, G.E. Henderson and P.S. Appelbaum, “Distributive justice, diversity, and inclusion in precision medicine: what will success look like?“ Genetics in Medicine (19) 2017, p. 157–159.
View in Google Scholar

Culyer, Wagstaff [1993] – A.J. Culyer and A. Wagstaff, “Equity and equality in health and health care,“ Journal of health economics (12/4) 1993, p. 431–457.
View in Google Scholar

Daniels [1985] – N. Daniels, Just health care, Cambridge University Press, Cambridge 1985.
View in Google Scholar

Daniels [2007] – N. Daniels, Just health: meeting health needs fairly, Cambridge University Press, Cambridge 2007.
View in Google Scholar

De Grandis, Halgunset [2016] – G. De Grandis and V. Halgunset, “Conceptual and Terminological Confusion Around Personalised Medicine: A Coping Strategy,” BMC Medical Ethics (17/43) 2016, p. 1–12.
View in Google Scholar

Downing [2009] – G.J. Downing, “Policy perspectives on the emerging pathways of personalized medicine,” Dialogues Clinical Neuroscience (11/4) 2009, p. 377–387.
View in Google Scholar

Drew [2016] – L. Drew “Pharmacogenetics: The right drug for you,” Nature (537/7619) 2016, p. 60–62.
View in Google Scholar

Dudley, Luft [1999] – R.A. Dudley and H.S. Luft, “Goals, targets, and tactics: Making health care policy decisions explicit,” Journal of Health Politics, Policy and Law (24/4) 1999, p. 705–713.
View in Google Scholar

Duster [2015] – T. Duster, “A post‐genomic surprise. The molecular reinscription of race in science, law and medicine,“ The British journal of sociology (66/1) 2015, p. 1–27.
View in Google Scholar

ESF – EMRC [2011] – European Science Foundation - European Medical Research Council, “A stronger Biomedical Research for a Better European Future,” White Paper (II) 2011.
View in Google Scholar

Evans, Khoury [2013] – J.P. Evans and M.J. Khoury, “The arrival of genomic medicine to the clinic is only the beginning of the journey,” Genetics in Medicine (15/4) 2013, p. 268–269.
View in Google Scholar

Fleck [2007] – L.M. Fleck, Just Caring. Health Care Rationing and Democratic Deliberation, Oxford University Press, New York 2007.
View in Google Scholar

Fleck [2014] – L.M. Fleck, “Just caring: Assessing the ethical and economic costs of personalized medicine,” Urologic Oncology: Seminars and Original Investigations (32/2) 2014, p. 202–206.
View in Google Scholar

Foster et al. [2006] – M.W. Foster, J.J. Mulvihil and R.R. Sharp, “Investments in cancer genomics: Who benefits and who decides,” American journal of public health (96/11) 2006, p. 1960–1964.
View in Google Scholar

Gassmann et al. [2008] – O. Gassmann, G. Reepmeyer and M. von Zedtwitz, Leading pharmaceutical innovation: trends and drivers for growth in the pharmaceutical industry, Springer, Berlin and Heidelberg 2008.
View in Google Scholar

Gibson, Tigerstrom von [2015] – S. Gibson and B. von Tigerstrom, “Orphan drug incentives in the pharmacogenomic context: policy responses in the US and Canada,“ Journal of Law and the Biosciences (2/2) 2015, p. 263–291.
View in Google Scholar

Ginsburg, Willard [2009] – G.S. Ginsburg and H.F. Willard, “Genomic and personalized medicine: foundations and applications,” Translational Research (154/6) 2009, p. 277–287.
View in Google Scholar

Goozner [2004] – M. Goozner, The $ 800 Million Pill: The Truth Behind the Cost of New Drugs, University of California Press, Berkeley – Los Angeles – London 2004.
View in Google Scholar

Gronowicz [2016] – G. Gronowicz, Personalized Medicine. Promises and Pitfalls, CRC Press, Boca Raton – London – New York 2016.
View in Google Scholar

Harvey et al. [2012] – A. Harvey, A. Brand, S.T. Holgate, L.V. Kristiansen, H. Lehrach, A. Palotie and B. Prainsack, “The future of technologies for personalised medicine,” New biotechnology (29/6) 2012, p. 625–633.
View in Google Scholar

Herder [2017] – M. Herder, “What Is the Purpose of the Orphan Drug Act?“ PLoS medicine (14/1) 2017, e1002191.
View in Google Scholar

Hopkins et al. [2007] – M.M. Hopkins, P.A. Martin, P. Nightingale, A. Kraft, and S. Mahdi, “The myth of the biotech revolution: An assessment of technological, clinical and organisational change,“ Research policy (36/4) 2007, p. 566–589.
View in Google Scholar

Hunt, Khosla [2010] – P. Hunt and R. Khosla, “Are Drug Companies Living Up to Their Human Rights Responsibilities? The Perspective of the Former United Nations Special Rapporteur (2002-2008),” PLoS Medicine (7/9) 2010, e1000330.
View in Google Scholar

Issa [2002] – A.M. Issa, “Ethical perspectives on pharmacogenomic profiling in the drug development process,” Nature reviews Drug discovery (1/4) 2002, p. 300–308.
View in Google Scholar

Issa [2015] – A.M. Issa, “10 years of personalizing medicine: how the incorporation of genomic information is changing practice and policy,” Personalized Medicine (12/1) 2015, p. 1–3.
View in Google Scholar

James [2014] – J.E. James, “Personalised medicine, disease prevention, and the inverse care law: more harm than benefit?” European journal of epidemiology (29/6) 2014, p. 383–390.
View in Google Scholar

Janssens, Deverka [2014] – A.C.J.W. Janssens and P.A. Deverka, “Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing,” Clinical Pharmacology & Therapeutics (96/6) 2014, p. 652–654.
View in Google Scholar

Johnson [2013] – J.A. Johnson, “Pharmacogenetics in clinical practice: how far have we come and where are we going?” Pharmacogenomics (14/7) 2013, p. 835–843.
View in Google Scholar

Jones [2011] – D.S. Jones, “How personalized medicine became genetic, and racial: Werner Kalow and the formations of pharmacogenetics,” Journal of the history of medicine and allied sciences (68/1) 2011, p. 1–48.
View in Google Scholar

Jonsen [2000] – A.R. Jonsen, A Short History of Medical Ethics, Oxford University Press, New York 2000.
View in Google Scholar

Joyner, Paneth [2015] – M.J. Joyner and N. Paneth, “Seven questions for personalized medicine”, JAMA 314 (10) 2015, p. 999–1000.
View in Google Scholar

Khoury, Galea [2016] – M.J. Khoury and S. Galea, “Will Precision Medicine Improve Population Health?” JAMA 316 (13) 2016, p. 1357–1358.
View in Google Scholar

Langreth, Waldholz [1999] – R. Langreth and M. Waldholz, “New Era of Personalized Medicine Targeting Drugs for Each Unique Genetic Profile,” The oncologist (4/5) 1999, p. 426–427.
View in Google Scholar

Leyens et al. [2014] – L. Leyens, D. Horgan, J.A. Lal, K. Steinhausen, K. Satyamoorthy and A. Brand, “Working towards personalization in medicine: main obstacles to reaching this vision from today's perspective,” Personalized Medicine (11/7) 2014, p. 641–649.
View in Google Scholar

Mackenbach [2006] – J.P. Mackenbach, Health inequalities: Europe in profile, UK Presidency of the EU 2005, s.l. 2006.
View in Google Scholar

Martin et al. [2006] – P. Martin, G. Lewis, A. Smart and A. Webster, False positive? The commercial and clinical development of pharmacogenetics, University of Nottingham, University of York & University of Bath, Nottingham & York 2006.
View in Google Scholar

Martin et al. [2013] – P. Martin, M. Hopkins, P. Nightingale & A. Kraft, On a Critical Path. Genomics, the Crisis of Pharmaceutical Productivity and the Search for Sustainability, [in:] Handbook of Genetics and Society. Mapping the New Genomic Era, P. Atkinson, P. Glasner & M. Lock (eds), Routledge, Abingdon UK and New York 2013, p. 145–162.
View in Google Scholar

NRC [2011] – National Research Council, Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease, The National Academies Press, Washington, DC 2011.
View in Google Scholar

O’Sullivan et al. [2013] – B.P. O’Sullivan, D.M. Orenstein and C.E. Milla, “Pricing for orphan drugs: will the market bear what society cannot?” Jama (310/13) 2013, p. 1343–1344.
View in Google Scholar

Peterson-Iyer [2008] – K. Peterson-Iyer, “Pharmacogenomics, ethics, and public policy,” Kennedy Institute of Ethics Journal (18/1) 2008, p. 35–56.
View in Google Scholar

Pokorska-Bocci et al. [2014] – A. Pokorska-Bocci, A. Stewart, G.S. Sagoo, A. Hall, M. Kroese and H. Burton, “’Personalized medicine’: what's in a name?” Personalized Medicine (11/2) 2014, p. 197–210.
View in Google Scholar

Powers, Faden [2005] – M. Powers and R. Faden, Social Justice. The Moral Foundations of Public Health and Health Policy, Oxford University Press, Oxford 2005.
View in Google Scholar

Prainsack, Buyx [2017] – B. Prainsack and A. Buyx, Solidarity in Biomedicine and Beyond, Cambridge University Press, Cambridge 2017.
View in Google Scholar

Prasad [2016] – V. Prasad, “The precisiononcology illusion,” Nature 537 (7619), S63, 2016.
View in Google Scholar

Rai [2002] – A.K. Rai, “Pharmacogenetic interventions, orphan drugs, and distributive justice: the role of cost-benefit analysis,” Social Philosophy and Policy (19/02) 2002, p. 246–270.
View in Google Scholar

Robertson et al. [2002] – J.A. Robertson, B. Brody, A. Buchanan, J. Kahn, and E. McPherson, “Pharmacogenetic challenges for the health care system,” Health Affairs (21/4) 2002, p. 155–167.
View in Google Scholar

Rothstein, Epps [2001] – M.A. Rothstein and P.G. Epps, “Ethical and legal implications of pharmacogenomics,” Nature Reviews Genetics (2/3) 2001, p. 228–231.
View in Google Scholar

Sachs [2015] – J. Sachs, “The Drug that Is Bankrupting America”, The Huffington Post 16.02.2015, URL = http://www.huffingtonpost.com/jeffrey-sachs/the-drug-that-is-bankrupt_b_6692340.html [15.12.2016].
View in Google Scholar

Shaw et al. [1999] – M. Shaw, D. Dorling, D. Gordon, and G.D. Smith, The widening gap: health inequalities and policy in Britain, Policy Press, Bristol 1999.
View in Google Scholar

Simoens et al. [2012] – S. Simoens, D. Cassiman, M. Dooms and E. Picavet, “Orphan Drugs for Rare Diseases,” Drugs 72 (11) 2012, p. 1437–1443.
View in Google Scholar

Slaughter [2012] – R.L. Slaughter, “Translation of pharmacogenetics to clinical practice: what will it take?” Expert review of clinical pharmacology (5/2) 2010, p. 101–103.
View in Google Scholar

Smart et al. [2004] – A. Smart, P. Martin and M. Parker, “Tailored medicine: whom will it fit? The ethics of patient and disease stratification,” Bioethics (18/4) 2004, p. 322–343.
View in Google Scholar

Squassina et al. [2010] – A. Squassina, M. Manchia, V.G. Manolopoulos, M. Artac, C. Lappa-Manakou, S. Karkabouna, K. Mitropoulos, M. Del Zompo and G.P. Patrinos, “Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice,” Pharmacogenomics (11/8) 2010, p. 1149–1167.
View in Google Scholar

Tutton [2012] – R. Tutton, “Personalizing medicine: Futures, present and past,” Social Science and Medicine (75) 2012, p. 1721–1728.
View in Google Scholar

UN CESCR [2000] – United Nations Committee on Economic, Social and Cultural Rights (CESCR), General Comment No. 14: The Right to the Highest Attainable Standard of Health (Art. 12 of the Covenant), Geneva 2000.
View in Google Scholar

Washington [2011] – H.A. Washington, Deadly monopolies: the shocking corporate takeover of life itself—and the consequences for your health and our medical future, Doubleday, New York 2011.
View in Google Scholar

Wellman-Labadie, Zhou [2010] – O. Wellman-Labadie and Y. Zhou, ”The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?” Health Policy (95/2) 2010, p. 216–228.
View in Google Scholar

Wilkinson, Marmot [2003] – R. Wilkinson and M. Marmot, The solid facts. Social determinants of health, World Health Organization Regional Office for Europe, Copenhagen 2005.
View in Google Scholar